Mainz Biomed to Reveal Pancreatic Cancer Study at AACR 2026

Mainz Biomed N.V., a company specializing in cancer diagnostics, will present findings at the AACR 2026 Annual Meeting. The event, organized by the American Association for Cancer Research, will be held from April 17 to 22 in San Diego, California. Mainz Biomed will share their results on a blood-based mRNA signature study aimed at detecting pancreatic ductal adenocarcinoma (PDAC) and differentiating it from benign conditions like intraductal papillary mucinous neoplasms (IPMN).

The study utilizes mRNA biomarkers and an AI-assisted modeling approach tested on a 30-subject cohort. The company believes this innovation could revolutionize pancreatic cancer screening and contribute to reducing mortality rates worldwide. More detailed findings will be published in the AACR's online proceedings.